Skip to main content
. 2014 Feb 20;25(5):1004–1011. doi: 10.1093/annonc/mdu053

Figure 2.

Figure 2.

Comparison of survival outcomes between patients with ER-positive tumors at 1%–9% and patients with ER-positive tumors ≥10% among patients: (A) distant recurrence-free survival, (B) recurrence-free survival, (C) overall survival; upper received endocrine therapy; lower: not received endocrine therapy.